Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06243926
Other study ID # e.23.I
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 8, 2024
Est. completion date June 2024

Study information

Verified date February 2024
Source CREA Medicina de la Reproducción SL
Contact Minerva Ferrer-Buitrago, BSc, PGDip, PhD
Phone +34622342562
Email minerva.ferrer@creavalencia.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Microfluidics technologies are proving their capability to select suitable sperm for ICSI, especially those that take advantage of the rheotaxic properties of sperm migration. In contrast to other sperm preparation methods such as Wash-Swim-Up and Density- Gradients-Centrifugation (DGC), microfluidics disregards washing and centrifugation steps along the procedure. However, microfluidics devices are costly and likely to fail to select motile sperm in dispermic samples. The investigators have recently described a novel approach for sperm selection by In-Situ handmade rheotaxis microfluidics of fluidic walls in the same ICSI plate. This methodology integrates a swim-over based on horizontal migration with a positive rheotaxis zone. The present study aims to deliver an unbiased comparison between two sperm selection techniques: DGC and In-Situ handmade rheotaxis microfluidics of fluidic walls (isM).


Description:

Microfluidics technologies stand as the latest sperm selection methodology for ICSI. Increasingly, publications show novel and ingenious microfluidics strategies to integrate sperm biomimicry during in vitro sperm selection while simplifying the IVF workflow. Microfluidics are time-efficient methods which reduce the risks associated with handling, gamete mix-up and ROS production. However, microfluidics devices are costly and likely to fail to select motile sperm in dispermic samples. Aiming to outline the application of microfluidics in ART, the investigators conceived a lab-on-a-chip approach for sperm selection by In-Situ rheotaxis handmade microfluidics of fluidic walls. This microfluidics system allows selecting sperm for ICSI in the same ICSI-dish. Thus, from a microvolume of the raw semen sample, only using microfluidics, disregarding centrifugation, washing, plasticware, other cells, products or materials, and using the same culture medium needed to prepare the rest of the ICSI plate. A previous proof-of-concept study showed that this methodology efficiently selected suitable sperm for ICSI. The investigators also demonstrated that the microfluidic protocol effectively separates at least 20 progressive spermatozoa in less than 15 minutes in a clean microdroplet, free of any remaining seminal plasma. A subsequent non-inferiority study showed that the microfluidic method performs as well as density gradient centrifugation to achieve ICSI outcomes such as fertilization and day-5 blastocyst formation rate, proving that In-Situ handmade rheotaxis microfluidics of fluidic walls are also effective in supporting pre-implantation embryonic development in vitro.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - Patients undergoing ICSI - Female age under 40 years old - Number of mature oocytes (MII) upon oocyte retrieval = 6 - Male age under 50 years old - Total number of progressive sperm = 1 million Exclusion Criteria: - Patients with surgically retrieved sperm for ICSI - Cases using cryopreserved oocytes - Cases using cryopreserved sperm

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Sperm selection for ICSI
Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.

Locations

Country Name City State
Spain CREA Medicina de la Reproducción Valencia

Sponsors (1)

Lead Sponsor Collaborator
CREA Medicina de la Reproducción SL

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fertilization Rate (FR) The proportion of two-pronuclei zygote divided by the total number of matured and microinjected oocytes (2pn/MII, %) 16 to 20 hours post-ICSI (day 1)
Primary Day 5 usable blastocyst rate (D5UBR) The proportion of embryos classified as blastocysts at day 5 of development, which has been transferred and/or cryopreserved. 108 to 113 hours post-ICSI (day 5)
Primary Blastocyst quality grade Blastocysts are categorized following the scale described by the Spanish Association of Reproduction Biology Studies (ASEBIR). The ASEBIR classification categorizes blastocysts based on their morphology into four groups: from A (highest, better outcome) to D (lowest, worse outcome). 108 to 113 hours post-ICSI (day 5)
Secondary Morphokinetics profile (MK PNa) The proportion of embryos showing the appearance of pronuclei (PNa) out of the expected time frame. from 16 to 20 hours post-ICSI (day 1)
Secondary Morphokinetics profile (MK PNf) The proportion of embryos showing the fading of pronuclei (PNf) out of the expected time frame. from 24 to 25 hours post-ICSI (day 1)
Secondary Morphokinetics profile (MK t2) The proportion of embryos showing 2 cells (t2) out of the expected time frame. from 24 to 28 hours post-ICSI (day 1)
Secondary Morphokinetics profile (MK t4) The proportion of embryos showing 4 cells (t4) out of the expected time frame. from 37 to 41hours post-ICSI (day 2)
Secondary Morphokinetics profile (MK t8) The proportion of embryos showing 8 cells (t8) out of the expected time frame. from 51 to 69 hours post-ICSI (day 3)
Secondary Morphokinetics profile (MK tM) The proportion of embryos with full cell compaction (morula; tM) out of the expected time frame. from 81 to 96 hours post-ICSI (day 4)
Secondary Morphokinetics profile (MK tSB) The proportion of embryos starting to blastulate (tSB) out of the expected time frame. from 99 to 101 hours post-ICSI (day 5)
Secondary Morphokinetics profile (MK tB) The proportion of embryos starting to blastulate (tB) out of the expected time frame. from 108 to 113 hours post-ICSI (day 5)
Secondary Implantation Rate (IR) The proportion of embryos that were transferred that develop to a gestational sac 5 to 6 gestational weeks
Secondary Ongoing clinical pregnancy Rate (OCP) The proportion of embryos that were transferred that develop at least to the stage of fetal heart activity 6 to 8 gestational weeks
See also
  Status Clinical Trial Phase
Completed NCT05567731 - Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve N/A
Not yet recruiting NCT03680690 - Pregnancy Rate in Women With Normal Uterine Cavity and Those With Corrected Uterine Lesions in ICSI Cycles
Active, not recruiting NCT04751084 - Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment N/A
Completed NCT05724979 - Outcome of Using Sperm Bound to the Zona Pellucida of Immature Oocytes for Intracytoplasmic Sperm Injection (ICSI) N/A
Completed NCT03033563 - ICSI Outcome of Ejaculated Versus Extracted Testicular Spermatozoa N/A
Terminated NCT00866034 - Cetrotide Treatment Optimization Phase 4
Completed NCT04727671 - Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. Phase 4
Completed NCT04724343 - Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. Phase 4
Completed NCT05578118 - Health of Children Born From ICSI With AOA (AOA-BABIES)
Completed NCT04724486 - Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI Phase 4
Completed NCT04727684 - Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI Phase 4